Антибиотики и внебольничные инфекции нижних дыхательных путей. Кому? Какой?

Александр Игоревич Синопальников

doi:10.36488/cmac.2019.1.27-38

Антибиотики и внебольничные инфекции нижних дыхательных путей. Кому? Какой?

Клиническая микробиология и антимикробная химиотерапия. 2019; 21(1):27-38

Синопальников А.И.

10.36488/cmac.2019.1.27-38

внебольничные инфекции острый бронхит ХОБЛ внебольничная пневмония антибиотики антибактериальная терапия

Раздел

Болезни и возбудители

Тип

Журнальная статья

Публикация

Клиническая микробиология и антимикробная химиотерапия. 2019; 21(1):27-38

Аннотация Авторы Литература PDF Статистика Репринты

Аннотация

В данной статье обсуждается этиология, характеристики пациентов, данные по антибиотикорезистентности, а также другие факторы, определяющие показания к назначению и выбор соответствующих антибиотиков для лечения инфекций нижних дыхательных путей, таких как острый бронхит, внебольничная пневмония и обострение хронической обструктивной болезни лёгких, с учётом принципов рациональной антибактериальной терапии.

Синопальников Александр Игоревич

aisyn@list.ru

0000-0002-1990-2042

ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия

1. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2095-2128. DOI: 10.1016/S01406736(12)61728-0
2. Lim S.S., Vos T., Flaxman A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;80:2224-2260. DOI: 10.1016/S0140-6736(12)61766-8
3. Murray C.J., Vos T., Lozano R., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2197-2223. DOI: 10.1016/S0140-6736(12)61689-4
4. Fleming-Dutra K.E., Hersh A.L., Shapiro D.J., et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA. 2016;315:1864-1873. DOI: 10.1001/jama.2016.4151
5. Bartlett JG. Management of respiratory tract infections. 2nd Ed. Lippincott Williams & Wilkins. Philadelphia, 1999.
6. Kraus E.M., Pelzl S., Szecsenyi J., Laux G. Antibiotic prescribing for acute lower respiratory tract infections (LRTI) – guideline adherence in the German primary care setting: An analysis of routine data. PLoS One. 2017;12(3):e0174584. DOI: 10.1371/journal.pone.0174584
7. McCullogh A.R., Pollack A.L., Hansen M.P., et al. Antibiotics for acute infections in general practice: comparison of prescribing rates with guideline recommendations. Med J Aust. 2017;207:65-69. DOI: 10.5694/mja16.01042
8. Harbarth S., Balkhy H.H., Goossens H., et al. Antimicrobial resistance: one world, one fight! Antimicrob Resist Infect Control. 2015;4:49. DOI: 10.1186/s13756-015-0091-2
9. Zumla A., Memish Z.A., Maeurer M., et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis. 2014;14:1136-1149. DOI: 10.1016/S1473-3099(14)70828-X
10. Appelbaum P.C. 2012 and beyond: potential for start of a second preantibiotic era? J Antimicrob Chemother. 2012;67:2062-2068. DOI: 10.1093/jac/dks213
11. Gould I.M., Bal A.M. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;4:185191. DOI: 10.4161/viru.22507
12. Ball P., Baquero F., Cars O., et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002;49:31-40. DOI: 10.1093/jac/49.1.31
13. Schappert S.M. Ambulatory care visits to physician offices, hospital outpatient department, and emergency departments, United States, 1997. Vital and Health Statistics, Series 13. Hyattsville, MD: National Center for Health Statistics; 1999. DHHS publications no. (PHS) 2000. p. 1714.
14. Llor C. Acute bronchitis: aetiology and treatment. Eur Respir Monogr. 2013;60:1-17. DOI: 10.1183/1025448x.10016912
15. Macfarlane J., Holmes W., Gard P., et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001;56:109-114. DOI: 10.1136/thorax.56.2.109
16. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:11381180. DOI: 10.1183/09031936.05.00055705
17. Benninger M., Segreti J. Is it bacterial or viral? Criteria for distinguishing bacterial and viral infections. J Fam Prac. 2008;57(2 Suppl):S5-11.
18. Breath sounds. From basic science to clinical practice. Eds. K.N. Priftis, L.J. Hadjileontiadis, M.L. Evard. Springer International Publishing AG; Cham, Switzerland. 2018.
19. Sinopalnikov A.I., Kozlov R.S. Community-acquired respiratory tract infections. Guidelines for practitioners. M.: Prem’er MT, Nash Gorod, 2007. 352 p. Russian. (Синопальников А.И., Козлов Р.С. Внебольничные инфекции дыхательных путей. Руководство для врачей. М.: Премьер МТ, Наш Город, 2007. 352 с.).
20. Claessens Y.E., Debray M.P., Tubach F., et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015;192:974-982. DOI: 10.1164/rccm.201501-0017OC
21. Aqassandjan M., Shurin G.V., Ma Y., Shurin M.R. C-reactive protein and lung diseases. Int J Biochem Cell Biol. 2014;53:77-88. DOI: 10.1016/j.biocel.2014.05.016
22. Brink A.J., Van Wyk J., Moodley V.M., et al. The role of appropriate diagnostic testing in acute tract infections: an antibiotic stewardship strategy to minimize diagnostic uncertainty in primary care. S Afr Med J. 2016;106:30-37. DOI: 10.7196/SAMJ.2016.v106i6.10857
23. Wark P. Bronchitis (acute). BMJ Clin Evid. 2015;7:1508-1536.
24. Ott S.R., Rohde G., Lepper P.M., et al. The impact of viruses in lower respiratory tract infections of the adult. Part II: acute bronchitis, acute exacerbated COPD, pneumonia, and influenza. Pneumologie. 2010;64:18-27. DOI: 10.1055/s-0029-1215197
25. Martinez F.J. Acute bronchitis: state of the art diagnosis and therapy. Compr Ther. 2004;30:55-69.
26. Liapikou A., Torres A. The clinical management of lower respiratory tract infections. Expert Rev Respir Med. 2016;10:441-452. DOI: 10.1586/17476348.2016.1156537
27. Rohani P., Drake J.M. The decline and resurgence of pertussis in the US. Epidemics. 2011;3:183-188. DOI: 10.1016/j.epidem.2011.10.001
28. Masseria C., Krishnarajah G. The estimated incidence of pertussis in people aged 50 years old in the United States, 2006-2010. BMC Infect Dis. 2015;15:534. DOI: 10.1186/s12879-015-1269-1
29. Gerber J.S. Improving Outpatient Antibiotic Prescribing: Another Nudge in the Right Direction. JAMA. 2016;315:558-559. DOI: 10.1001/jama.2016.0430
30. Evertsen J., Baumgardner D.J., Regnery A., et al. Diagnosis and management of pneumonia and bronchitis in outpatient primary care practices. Prim Care Respir J. 2010;19:237-241. DOI: 10.4104/pcrj.2010.00024
31. Harris A.M., Hicks L.A., Qaseem A., et al. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164:425-434. DOI: 10.7326/M15-1840
32. Smith S.M., Fahney T., Smucny J., Becker L.A. Antibiotic for acute bronchitis (Review). Cochrane Database Syst Rev. 2017;6:CD 000245. DOI: 10.1002/14651858.CD000245.pub4
33. Harris A.M., Hicks L.A., Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164:425-434. DOI: 10.7326/M15-1840
34. Tan T., Little P., Stokes T. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ. 2008;337:a437. DOI: 10.1136/bmj.a437
35. Respiratory tract infections (self-limiting): prescribing antibiotics. Clinical guideline [CG69]. Available at: www.nice.org.uk/CG069. Accessed 28.10.2015.
36. Kozlov R.S., Zyryanov S.K., Synopalnikov A.I., Ryazantsev S.V., Styrt E.A. Resolution of the Expert Council «Empirical antibacterial therapy of respiratory infections and the risk factors of resistant flora». Spravochnik poliklinicheskogo vracha. 2018;1:28-32. Russian. (Козлов Р.С., Зырянов С.К., Синопальников А.И., Рязанцев С.В., Стырт Е.А. Эмпирическая антибактериальная терапия инфекций дыхательных путей с учетом факторов риска резистентной флоры. Резолюция совета экспертов. Справочник поликлинического врача. 2018;1:28-32.).
37. Altunaiji S.M., Kukuruzovic R.H., Curtis N.C., et al. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2007;3:CD004404. DOI: 10.1002/14651858.CD004404.pub3
38. Macfarlane J. Lower respiratory tract infection and pneumonia in the community. Sem Respir Infect. 1999;14:151-162.
39. Hoyert D.L., Xu J. Death: preliminary data for 2011. Natl Vital Stat Rep. 2012;61:1-51.
40. Austrian R., Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 1964;60:759776. DOI: 10.7326/0003-4819-60-5-759
41. Ewig S., Birkner N., Strauss R., et al. New perspectives on communityacquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64:1062-1069. DOI: 10.1136/thx.2008.109785
42. Cilloniz C., Rodriguez-Hurtado D., Torres A. Characteristics, and management of community-acquired pneumonia in the era of global aging. Med Sci. 2018;6:35-52. DOI: 10.3390/medsci6020035
43. Cilloniz C., Ardanuy C., Vila J., Torres A. What is the clinical relevance of drug-resistant pneumococcus? Curr Opin Pulm Med. 2016;22:227234. DOI: 10.1097/MCP.0000000000000262
44. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012;67:71-79. DOI: 10.1136/thx.2009.129502
45. Herrero S.F., Olivas B. Microbiology and risk factors for communityacquired pneumonia. Semin Respir Crit Care Med. 2012;33:220-231. DOI: 10.1055/s-0032-1315634
46. Musher D.M., Abers M.S., Bartlett J.G. Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus. Clin Infect Dis. 2017;65:1736-1744. DOI: 10.1093/cid/cix549
47. Marchello C., Dale A.P., Thai T.N., et al. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis. Ann Fam Med. 2016;14:552-566. DOI: 10.1370/afm.1993
48. Cilloniz C., Torres A., Niederman M., et al. Community-acquired pneumonia related to intracellular pathogens. Intensive Care Med. 2016;42:1374-1386. DOI: 10.1007/s00134-016-4394-4
49. Community-acquired pneumonia. Clinical guidelines (project), 2018. Available at: www.antibiotic.ru. Russian. (Внебольничная пневмония. Клинические рекомендации (проект), 2018. Доступно по адресу: www.antibiotic.ru).
50. Gleason P.P., Meehan T.P., Fine J.M., et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159:2562-2572. DOI: 10.1001/archinte.159.21.2562
51. Meehan T.P., Fine M.J., Krumholz H.M., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278:20802084. DOI: 10.1001/jama.1997.03550230056037
52. Houck P.M., Bratzler D.W., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637644. DOI: 10.1001/archinte.164.6.637
53. Bjerre L.M., Verheij T.J., Kochen M.M. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2009;4:CD002109. DOI: 10.1002/14651858.CD002109.pub3
54. Torumkuney D., Mayanskiy N., Edelstein M., et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia. J Antimicrob Chemother. 2018;73(suppl_5):v14-v21. DOI: 10.1093/jac/dky065
55. Cherazard R., Epstein M., Doan T.L., et al. Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications. Am J Ther. 2017;24:361-369. DOI: 10.1097/MJT.0000000000000551
56. Wiersinga W.J., Bonten M.J., Boersma W.G., et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth Med J. 2018;76:4-13.
57. Boyles T.H., Brink A., Calligaro G.L., et al. South Africa guideline for the management of community-acquired pneumonia in adults. J Thorac Dis. 2017;9:1469-1502. DOI: 10.21037/jtd.2017.05.31
58. Garin N., Genne D., Carballo S., et al. Β-Lactam monotherapy vs Β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174:1894-1901. DOI: 10.1001/jamainternmed.2014.4887
59. Ranzani O.T., Taniguchi L.U., Torres A. Severity scoring systems for pneumonia: current understanding and next steps. Curr Opin Pulm Med. 2018;24:227-236. DOI: 10.1097/MCP.0000000000000468
60. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250. DOI: 10.1056/NEJM199701233360402
61. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-382. DOI: 10.1136/thorax.58.5.377
62. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-S72. DOI: 10.1086/511159
63. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375-384. DOI: 10.1086/589754
64. Espana P.P., Capelastegui A., Gorordo I., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174:1249-1256. DOI: 10.1164/rccm.200602-177OC
65. Singer M., Deutschman C.S., Seymour C.W., et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-810. DOI: 10.1001/jama.2016.0287
66. Zhang Y.Q., Zou S.L., Zhao H., et al. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. Am J Emerg Med. 2018;36(10):17591765. DOI: 10.1016/j.ajem.2018.01.079
67. Raz-Pasteur A., Shasha D., Paul M. Fluoroquinolones or macrolides alone versus combined with Β-lactams for adults with communityacquired pneumonia: Systematic review and meta-analysis. Int J Antimicrob Agents. 2015;46:242-248. DOI: 10.1016/j.ijantimicag.2015.04.010
68. Ruhe J., Mildvan D. Does empirical therapy with a fluoroquinolone or the combination of a Β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward? Infect Dis Clin North Am. 2013;27:115-132. DOI: 10.1016/j.idc.2012.11.004
69. Postma D.F., van Werkhoven C.H., van Elden L.J., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312-1323. DOI: 10.1056/NEJMoa1406330
70. Hajj E.L., Turgeon R.D., Wilby K.J. Ceftaroline fosamil for communityacquired pneumonia and skin and skin structure infections: a systematic review. Int J Clin Pharm. 2017;39:26-32. DOI: 10.1007/s11096016-0417-z
71. Ortiz-Ruiz G., Vetter N., Isaacs R., et al. Ertapenem versus for the treatment of community-acquired pneumonia in adults: combined analysis of two multicenter randomized, double-blind studies. J Antimicrob Chemother. 2004;53(Suppl 2):ii59-66. DOI: 10.1093/jac/dkh207
72. Murcia J.M., Gonzales-Comeche J., Marin A., et al. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. Clin Microbiol Infect. 2009;15:10461050. DOI: 10.1111/j.1469-0691.2009.02843.x
73. Lisboa T., Salluh J.L., Friedman G. Macrolides and respiratory infection in critically ill patients: what is the next step? Minerva Anestesiol. 2016;82:221-229.
74. Horita N., Otsuka T., Haranaga S., et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis. Respirology. 2016;21:1193-2000. DOI: 10.1111/resp.12835
75. Chuchalin A.G., Synopalnikov A.I., Kozlov R.S., et al. Clinical guidelines for the diagnosis, treatment and prevention of severe community-acquired pneumonia in adults, 2014. Available at: www.pulmonology.ru. Russian. (Чучалин А.Г., Синопальников А.И., Козлов Р.С. и соавт. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых, 2014. Доступно по адресу: www.pulmonology.ru).
76. Global initiative for Chronic Obstructive Lung Disease. GOLD Report 2018. Available at: www.copdgold.com.
77. Seemungal T.A., Donaldson G.C., Bhowmik A., et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608-1613. DOI: 10.1164/ajrccm.161.5.9908022
78. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., et al. Severe acute exacerbations and mortality in patients with COPD. Thorax. 2005;60:925-931. DOI: 10.1136/thx.2005.040527
79. Almagro P., Calbo E., Ochoahe Echaguen A., et al. Mortality after hospitalized for COPD. Chest. 2002;121:1441-1448. DOI: 10.1378/chest.121.5.1441
80. Bafadhel M., McKenna S., Terry S., et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662-671. DOI: 10.1164/rccm.201104-0597OC
81. George S.N., Garcha D.S., Mackay A.J., et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J. 2014;44:87-96. DOI: 10.1183/09031936.00223113
82. Siddiqi A., Sethi S. Optimizing antibiotic selection in treating COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2008;3:31-44. DOI: 10.2147/COPD.S1089
83. Allegra L., Blasi F., Diano P., et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med. 2005;99:742-747. DOI: 10.1016/j.rmed.2004.10.020
84. Eller J., Ede A., Schaberg T., et al. Infective exacerbations of chronic bronchitis: relation between bacterial etiology and lung function. Chest. 1998;113:1542-1548. DOI: 10.1378/chest.113.6.1542
85. Lode H., Allewelt M., Balk S., et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection. 2007;35:143-149. DOI: 10.1007/s15010-007-6078-z
86. Monso E., Garcia-Aymerich J., Soler N., et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 2003;131:799-804. DOI: 10.1017/S0950268803008872
87. Garcia-Vidal C., Almagro P., Romani V., et al. Pseudomonas aeruginosa in patients hospitalized for COPD exacerbation: a prospective study. Eur Respir J. 2009;34:1072-1078. DOI: 10.1183/09031936.00003309
88. Miravitlles M., Espinosa C., Fernandez-Laso E., et al. Study Group of bacterial infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40-46. DOI: 10.1378/chest.116.1.40
89. Gallego M., Pomares X., Espasa M., et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med. 2014;14:103. DOI: 10.1186/1471-2466-14-103
90. Anthonisen N.R., Manfreda J., Warren C.P., et al. Antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204. DOI: 10.7326/0003-4819-106-2-196
91. Puhan M.A., Vollenweider D.J., Latshang T., Steurer-Stey C.A. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res. 2007;8:30. DOI: 10.1186/1465-9921-8-30
92. Vollenweider D.J., Jarrett H., Steurer-Stey C.A., et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12:CD010257. DOI: 10.1002/14651858.CD010257
93. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic pulmonary obstructive disease in adults in primary and secondary care (partial update). London, National Clinical Guideline Centre, 2004.
94. Wedzicha J.A., Miravitlles M., Hurst J.R., et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3). pii: 1600791. DOI: 10.1183/13993003.00791-2016
95. Stockley R.A., O’Brien C., Pye A., Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638-1645. DOI: 10.1378/chest.117.6.1638
96. Miravitlles M., Kruesmann F., Haverstock D., et al. Sputum color and bacteria in chronic bronchitis exacerbations: A pooled analysis. Eur Respir J. 2012;39:1354-1360. DOI: 10.1183/09031936.00042111
97. Soler N., Agusti C., Angrill J., et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax. 2007;62:29-35. DOI: 10.1136/thx.2005.056374
98. Llor C., Moragas A., Hernandez S., et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate COPD. Am J Respir Crit Care Med. 2012;186:716-723. DOI: 10.1164/rccm.201206-0996OC
99. Celli B.R., MacNee W., ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946. DOI: 10.1183/09031936.04.00014304
100. Feldman C., Richards G. Appropriate antibiotic management of bacterial lower respiratory tract infections. F1000 Research. 2018;7:1121. DOI: 10.12688/f1000research.14226.1
101. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1-59. DOI: 10.1111/j.14690691.2011.03672.x
102. Rothberg M.B., Pekow P.S., Lahti M., et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303:20352042. DOI: 10.1001/jama.2010.672
103. Miravitlles M., Murio C., Guerrero T., et al. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17:928-933.
104. Wilson R., Schentag J.J., Ball P., Mandell L. 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002;24:639-652. DOI: 10.1016/S0149-2918(02)85139-6
105. Wilson R., Allegra L., Huchon G., et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953-964. DOI: 10.1378/chest.125.3.953
106. Ruiz-Gonzalez A., Gimenez A., Gomez-Arbones X., et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology. 2007;12:117-121. DOI: 10.1111/j.1440-1843.2006.00950.x
107. Miravitlles M., Anzueto A. Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:1052-1057.

Просмотров

0 Аннотация

0 PDF

0 Цитирования

Антибиотики и внебольничные инфекции нижних дыхательных путей. Кому? Какой?

Аннотация

Просмотров

Поделились

Процитировали Crossref